Asia Pacific Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026
The Asia Pacific Osteoporosis Drugs Market would witness market growth of 5.6% CAGR during the forecast period (2020-2026).
The Asia Pacific market is expected to rise in the coming years in a lucrative CAGR. The region's rapid growth is expected to be a result of steady R&D spending by the prominent actors and their attempts to market branded and generic medicine at a reasonably low price. The industry is expected to witness intense competition during the forecast period as a result of the increasing incorporation of collaborative strategies among key players to maintain a competitive position. High R&D investment, fusions, and acquisitions, and drug development agreements are the other strategies incorporated.
There has been a noticeable growth in people around the world's awareness of osteoporosis, which is a noticeable factor in the osteoporosis market. This recognition is primarily a result of numerous steps implemented across different programs and campaigns by public and private associations. For example, the International Foundation for Osteoporosis is an osteoporosis organization.
Due to the increase in R&D investment from major players in advanced novel bisphosphonate drugs, bisphosphonates acquired the major share in the osteoporosis market. Bisphosphonates are also widely used osteoporosis drugs, which stimulates market growth. However, the rank ligand inhibitor segment is expected to have the fastest growth rate during the forecast period, due to the fact that these drugs are used to treat bone metastases by acting as a chemoattractant to the bone for tumor cells that express its receptor, RANK. The RANKL-RANK pathway inhibition thus acts as an ideal treatment for bone metastasis.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Study
Market Segmentation:
By Route of Administration
The Asia Pacific market is expected to rise in the coming years in a lucrative CAGR. The region's rapid growth is expected to be a result of steady R&D spending by the prominent actors and their attempts to market branded and generic medicine at a reasonably low price. The industry is expected to witness intense competition during the forecast period as a result of the increasing incorporation of collaborative strategies among key players to maintain a competitive position. High R&D investment, fusions, and acquisitions, and drug development agreements are the other strategies incorporated.
There has been a noticeable growth in people around the world's awareness of osteoporosis, which is a noticeable factor in the osteoporosis market. This recognition is primarily a result of numerous steps implemented across different programs and campaigns by public and private associations. For example, the International Foundation for Osteoporosis is an osteoporosis organization.
Due to the increase in R&D investment from major players in advanced novel bisphosphonate drugs, bisphosphonates acquired the major share in the osteoporosis market. Bisphosphonates are also widely used osteoporosis drugs, which stimulates market growth. However, the rank ligand inhibitor segment is expected to have the fastest growth rate during the forecast period, due to the fact that these drugs are used to treat bone metastases by acting as a chemoattractant to the bone for tumor cells that express its receptor, RANK. The RANKL-RANK pathway inhibition thus acts as an ideal treatment for bone metastasis.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Study
Market Segmentation:
By Route of Administration
- Oral
- Injectable and
- Other Route of Administration
- Bisphosphonates
- Rank Ligand Inhibitors
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors Modulator (SERM) and
- Other Drug Classes
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Allergan PLC
- Eli Lilly and Company
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Osteoporosis Drugs Market, by Route of Administration
1.4.2 Asia Pacific Osteoporosis Drugs Market, by Drug Class
1.4.3 Asia Pacific Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION
3.1 Asia Pacific Oral Market by Country
3.2 Asia Pacific Injectable Market by Country
3.3 Asia Pacific Other Route of Administration Market by Country
CHAPTER 4. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS
4.1 Asia Pacific Bisphosphonates Market by Country
4.2 Asia Pacific Rank Ligand Inhibitors Market by Country
4.3 Asia Pacific Parathyroid Hormone Therapy Market by Country
4.4 Asia Pacific Calcitonin Market by Country
4.5 Asia Pacific Other Drug Class Market by Country
CHAPTER 5. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY
5.1 China Osteoporosis Drugs Market
5.1.1 China Osteoporosis Drugs Market by Route of Administration
5.1.2 China Osteoporosis Drugs Market by Drug Class
5.2 India Osteoporosis Drugs Market
5.2.1 India Osteoporosis Drugs Market by Route of Administration
5.2.2 India Osteoporosis Drugs Market by Drug Class
5.3 Japan Osteoporosis Drugs Market
5.3.1 Japan Osteoporosis Drugs Market by Route of Administration
5.3.2 Japan Osteoporosis Drugs Market by Drug Class
5.4 South Korea Osteoporosis Drugs Market
5.4.1 South Korea Osteoporosis Drugs Market by Route of Administration
5.4.2 South Korea Osteoporosis Drugs Market by Drug Class
5.5 Singapore Osteoporosis Drugs Market
5.5.1 Singapore Osteoporosis Drugs Market by Route of Administration
5.5.2 Singapore Osteoporosis Drugs Market by Drug Class
5.6 Malaysia Osteoporosis Drugs Market
5.6.1 Malaysia Osteoporosis Drugs Market by Route of Administration
5.6.2 Malaysia Osteoporosis Drugs Market by Drug Class
5.7 Rest of Asia Pacific Osteoporosis Drugs Market
5.7.1 Rest of Asia Pacific Osteoporosis Drugs Market by Route of Administration
5.7.2 Rest of Asia Pacific Osteoporosis Drugs Market by Drug Class
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Osteoporosis Drugs Market, by Route of Administration
1.4.2 Asia Pacific Osteoporosis Drugs Market, by Drug Class
1.4.3 Asia Pacific Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION
3.1 Asia Pacific Oral Market by Country
3.2 Asia Pacific Injectable Market by Country
3.3 Asia Pacific Other Route of Administration Market by Country
CHAPTER 4. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS
4.1 Asia Pacific Bisphosphonates Market by Country
4.2 Asia Pacific Rank Ligand Inhibitors Market by Country
4.3 Asia Pacific Parathyroid Hormone Therapy Market by Country
4.4 Asia Pacific Calcitonin Market by Country
4.5 Asia Pacific Other Drug Class Market by Country
CHAPTER 5. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY
5.1 China Osteoporosis Drugs Market
5.1.1 China Osteoporosis Drugs Market by Route of Administration
5.1.2 China Osteoporosis Drugs Market by Drug Class
5.2 India Osteoporosis Drugs Market
5.2.1 India Osteoporosis Drugs Market by Route of Administration
5.2.2 India Osteoporosis Drugs Market by Drug Class
5.3 Japan Osteoporosis Drugs Market
5.3.1 Japan Osteoporosis Drugs Market by Route of Administration
5.3.2 Japan Osteoporosis Drugs Market by Drug Class
5.4 South Korea Osteoporosis Drugs Market
5.4.1 South Korea Osteoporosis Drugs Market by Route of Administration
5.4.2 South Korea Osteoporosis Drugs Market by Drug Class
5.5 Singapore Osteoporosis Drugs Market
5.5.1 Singapore Osteoporosis Drugs Market by Route of Administration
5.5.2 Singapore Osteoporosis Drugs Market by Drug Class
5.6 Malaysia Osteoporosis Drugs Market
5.6.1 Malaysia Osteoporosis Drugs Market by Route of Administration
5.6.2 Malaysia Osteoporosis Drugs Market by Drug Class
5.7 Rest of Asia Pacific Osteoporosis Drugs Market
5.7.1 Rest of Asia Pacific Osteoporosis Drugs Market by Route of Administration
5.7.2 Rest of Asia Pacific Osteoporosis Drugs Market by Drug Class
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
LIST OF TABLES
TABLE 1 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 2 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 3 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 4 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 5 ASIA PACIFIC ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 ASIA PACIFIC ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 12 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 13 ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 CHINA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 26 CHINA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 27 CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 28 CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 29 CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 30 CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 31 INDIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 32 INDIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 33 INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 34 INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 35 INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 36 INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 37 JAPAN OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 38 JAPAN OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 39 JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 40 JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 41 JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 42 JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 43 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 44 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 45 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 46 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 47 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 48 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 49 SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 50 SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 51 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 52 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 53 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 54 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 55 MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 56 MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 57 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 58 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 59 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 60 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 61 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 62 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 63 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 64 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 65 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 66 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 67 KEY INFORMATION – AMGEN, INC.
TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 69 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 70 KEY INFORMATION - MERCK & CO., INC.
TABLE 71 KEY INFORMATION – NOVARTIS AG
TABLE 72 KEY INFORMATION – PFIZER, INC.
TABLE 73 KEY INFORMATION – SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 74 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 75 KEY INFORMATION – ALLERGAN PLC
TABLE 76 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 1 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 2 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 3 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 4 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 5 ASIA PACIFIC ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 ASIA PACIFIC ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 12 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 13 ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 CHINA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 26 CHINA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 27 CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 28 CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 29 CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 30 CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 31 INDIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 32 INDIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 33 INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 34 INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 35 INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 36 INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 37 JAPAN OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 38 JAPAN OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 39 JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 40 JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 41 JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 42 JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 43 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 44 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 45 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 46 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 47 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 48 SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 49 SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 50 SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 51 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 52 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 53 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 54 SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 55 MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 56 MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 57 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 58 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 59 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 60 MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 61 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 62 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 63 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 64 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 65 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 66 REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 67 KEY INFORMATION – AMGEN, INC.
TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 69 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 70 KEY INFORMATION - MERCK & CO., INC.
TABLE 71 KEY INFORMATION – NOVARTIS AG
TABLE 72 KEY INFORMATION – PFIZER, INC.
TABLE 73 KEY INFORMATION – SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 74 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 75 KEY INFORMATION – ALLERGAN PLC
TABLE 76 KEY INFORMATION – ELI LILLY AND COMPANY
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
